



Editorial

Understanding the complexities of post-tuberculosis lung disease: Implications for global health

Sankalp Yadav ¹*

¹Dept. of Medicine & Tuberculosis, Shri Madan Lal Khurana Chest Clinic, Moti Nagar, Municipal Corporation of Delhi, New Delhi, India



ARTICLE INFO

Article history:

Received 25-03-2024

Accepted 12-04-2024

Available online 25-04-2024

Keywords:

Chronic obstructive pulmonary disease

Post-tuberculosis lung disease

Tuberculosis

Quality of life

ABSTRACT

Post-tuberculosis lung disease (PTLD) presents a significant challenge in the management of tuberculosis patients, with far-reaching implications for global health. This editorial explores the multifaceted nature of PTLD, encompassing its pathophysiology, clinical manifestations, diagnostic complexities, and implications for public health. PTLD arises from pulmonary damage due to an active tuberculosis infection, leading to inflammation, scarring, and fibrosis within the lungs. Clinical manifestations vary widely, ranging from chronic respiratory symptoms to severe respiratory failure, often resembling chronic obstructive pulmonary disease or restrictive lung disease. The diagnosis of PTLD is hindered by its heterogeneous presentation and overlap with other respiratory conditions, necessitating a comprehensive evaluation through pulmonary function tests and radiological imaging. PTLD imposes a substantial burden on global health systems, particularly in regions with high tuberculosis prevalence, contributing to increased morbidity and mortality rates. Management strategies focus on alleviating symptoms, preserving lung function, and preventing disease progression through pharmacological interventions, pulmonary rehabilitation, and, in select cases, surgical interventions. Preventive measures include effective tuberculosis control measures, vaccination against respiratory pathogens, and addressing social determinants of health. Overall, a comprehensive understanding of PTLD is essential for improving patient outcomes and reducing disease burden, highlighting the importance of concerted efforts to raise awareness, enhance diagnostic capabilities, and develop effective management strategies for this complex condition.

This is an Open Access (OA) journal, and articles are distributed under the terms of the [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License](https://creativecommons.org/licenses/by-nc-sa/4.0/), which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprint@ipinnovative.com

1. Editorial

Tuberculosis continues to be a major global health concern, affecting millions of individuals worldwide each year.¹ While much attention is rightfully given to the diagnosis and treatment of active tuberculosis infection, the long-term consequences of tuberculosis extend beyond the initial infection. Post-tuberculosis lung disease (PTLD) represents a significant challenge in the management of tuberculosis patients, with potentially debilitating effects on respiratory function and overall quality of life.²

* Corresponding author.

E-mail address: drsankalpyadav@gmail.com (S. Yadav).

In this editorial, the complexities of PTLD, including its pathophysiology, clinical manifestations, diagnostic challenges, and implications for global health, are discussed.

PTLD arises as a consequence of the pulmonary damage caused by an active tuberculosis infection. The immune response to tuberculosis bacilli leads to inflammation and tissue destruction within the lungs, resulting in scarring, fibrosis, and bronchiectasis. These structural changes impair lung function and ventilation, predisposing individuals to chronic respiratory symptoms and complications.³

The clinical presentation of PTLD can vary widely, ranging from mild respiratory symptoms to severe

respiratory failure. Common manifestations include chronic cough, dyspnea, hemoptysis, and recurrent respiratory infections. Additionally, PTLD may lead to progressive airflow limitation, resembling chronic obstructive pulmonary disease or restrictive lung disease due to fibrotic changes.⁴

Diagnosing PTLD poses several challenges, primarily due to its heterogeneous presentation and overlap with other respiratory conditions. Pulmonary function tests often reveal obstructive or restrictive patterns, reflecting the underlying lung damage.⁵ Radiological imaging, such as chest X-rays or computed tomography scans, may demonstrate features of bronchiectasis, cavitation, fibrosis, or nodular opacities, but these findings are not specific to PTLD.⁶ Furthermore, microbiological confirmation of tuberculosis may be challenging in individuals with inactive or resolved tuberculosis infection.

PTLD represents a significant burden on global health systems, particularly in regions with high tuberculosis prevalence. The long-term sequelae of tuberculosis infection contribute to increased morbidity and mortality rates, further straining already resource-limited healthcare infrastructures.⁷ Additionally, PTLD disproportionately affects socioeconomically disadvantaged populations, exacerbating existing health disparities.⁴

Managing PTLD requires a comprehensive approach aimed at alleviating symptoms, preserving lung function, and preventing disease progression. Pharmacological interventions, such as inhaled bronchodilators, corticosteroids, and mucolytics, may help improve respiratory symptoms and reduce exacerbations.⁴ Pulmonary rehabilitation programs, including breathing exercises and physical therapy, can enhance exercise tolerance and quality of life.⁸ Surgical interventions, such as lung volume reduction surgery or lung transplantation, may be considered in select cases with advanced disease.⁴

Preventing PTLD begins with effective tuberculosis control measures, including early detection, prompt treatment initiation, and contact tracing to prevent transmission.⁹ Additionally, efforts to improve tuberculosis treatment adherence and address social determinants of health, such as poverty and malnutrition, are essential for reducing the incidence of PTLD.⁴ Vaccination against common respiratory pathogens, such as influenza and pneumococcus, can help reduce the risk of respiratory infections and complications in tuberculosis survivors.¹⁰

2. Conclusions

Post-tuberculosis lung disease represents a complex and often overlooked consequence of tuberculosis infection, with profound implications for global health. Understanding the pathophysiology, clinical manifestations, and diagnostic challenges of PTLD is crucial for improving patient outcomes and reducing disease burden. Moving forward,

concerted efforts are needed to raise awareness, enhance diagnostic capabilities, and develop effective management strategies for PTLD, ultimately improving the long-term health outcomes of tuberculosis survivors worldwide.

3. Source of Funding

None.

4. Conflicts of Interest

None declared.

Acknowledgements

None.

References

1. Yadav S, Rawal G, Jeyaraman M. India's decision to deny an extension of patent for bedaquiline: a public health imperative. *Cureus*. 2023;15(11):49542. doi:10.7759/cureus.49542.
2. Nuwagira E, Baluku JB, Meya DB, Philpotts LL, Siedner MJ, Bajunirwe F, et al. clinical features and outcomes of post-tuberculosis lung disease in sub-Saharan Africa: a protocol for a systematic review and meta-analysis. *BMJ Open*. 2022;12(8):e062260. doi:10.1136/bmjopen-2022-062260.
3. Cupido G, Günther G. Post tuberculosis lung disease and tuberculosis sequelae: A narrative review. *Indian J Tuberc*. 2024;71(1):64–72.
4. Nightingale R, Carlin F, Meghji J, Evans D, van der Zalm M, Anthony MG, et al. Post-TB health and wellbeing. *Int J Tuberc Lung Dis*. 2023;27(4):248–83.
5. Chushkin MI, Ots ON. Impaired pulmonary function after treatment for tuberculosis: the end of the disease? *J Bras Pneumol*. 2017;43(1):38–43.
6. Seo W, Kim HW, Kim JS, Min J. Long term management of people with post-tuberculosis lung disease. *Korean J Intern Med*. 2024;39(1):7–24.
7. Maleche-Obimbo E, Odhiambo MA, Njeri L, Mburu M, Jaoko W, Were F, et al. Magnitude and factors associated with post-tuberculosis lung disease in low- and middle-income countries: A systematic review and meta-analysis. *PLOS Glob Public Health*. 2022;2(12):805. doi:10.1371/journal.pgph.0000805.
8. Ando M, Mori A, Esaki H, Shiraki T, Uemura H, Okazawa M, et al. The effect of pulmonary rehabilitation in patients with post-tuberculosis lung disorder. *Chest*. 2003;123(6):1988–95.
9. Ma Y, Ye XP, Fu XY, Wu GH. Post-tuberculosis lung disease: a neglected disease. *Zhonghua Jie He He Hu Xi Za Zhi*. 2022;45(10):955–9.
10. Nasiri MJ, Silva DR, Rommasi F, Zahmatkesh MM, Tajabadi Z, Khelghati F, et al. Vaccination in post-tuberculosis lung disease management: A review of the evidence. *Pulmonology*. 2023;p. S2531–0437(23)00129–0. doi:10.1016/j.pulmoe.2023.07.002.

Author biography

Sankalp Yadav, General Duty Medical Officer-II  <https://orcid.org/0000-0001-6367-7228>

Cite this article: Yadav S. Understanding the complexities of post-tuberculosis lung disease: Implications for global health. *IP Indian J Immunol Respir Med* 2024;9(1):1-2.